Skip to main content
Solid Tumor Gastrointestinal Cancer

Gastrointestinal Cancer

FIT findings support CRC screening at age 45–49 years

People aged 45–49 years are as likely as those aged 50 years to complete a fecal immunochemical test within 3 months of receipt and undergo colonoscopy if they test positive.

Read more

Editor's Choice

Intraperitoneal chemotherapy for pancreatic cancer

What is the current evidence for the efficacy and safety of intraperitoneal chemotherapy in pancreatic cancer? Learn about the three different methods – NIPEC, HIPEC, and PIPAC – and the different drugs and doses.

Combination therapy for HCC

Delve into the current evidence and ongoing clinical trials for combinations of immunotherapeutic and targeted agents for the treatment of hepatocellular carcinoma.

TACE plus lenvatinib and pembrolizumab boosts HCC outcomes

Patients with intermediate-stage hepatocellular carcinoma derive a significant PFS benefit from the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization.

FITs performance variable for detection of colorectal neoplasia

Fecal immunohistochemical tests should not be considered interchangeable, due to significant differences in the ability to detect advanced colorectal neoplasia.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

  • Webinar | 19-02-2024 | 17:30 (CET)

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Watch now
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version

Case Studies

ICI-induced encephalitis in a patient with HCC

Only the third reported case of encephalitis in a patient receiving atezolizumab plus bevacizumab for advanced hepatocellular carcinoma. The neurological symptoms quickly improved once steroid pulse therapy was started.

Excellent response to immunotherapy in rare pancreatic cancer

A patient with pancreatic acinar cell carcinoma responded well to treatment with pembrolizumab and was able to undergo surgery. He remains disease-free 6 months after surgery.

Insulinoma misidentified as schizophrenia

Intermittently scanning CGM detected hypoglycemia in a woman previously diagnosed with schizophrenia and treated with antipsychotic medication. Insulinoma was diagnosed and resected, resolving her neuropsychiatric symptoms.

Case-based insights: Oncology and hematology (Link opens in a new window)


Refresh your knowledge in oncology and hematology: 

  • 45 clinical cases across different topics with relevant clinical images
  • Written by renowned experts 
  • Knowledge-check questions with answers
Try the first set of cases now

Current Reviews

The role of kinesin superfamily proteins in hepatocellular carcinoma

The most prevalent form of primary liver cancer, hepatocellular carcinoma (HCC) poses a significant global health challenge due to its limited therapeutic options. Researchers are currently focused on the complex molecular landscape that governs …

Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors

MicroRNAs (miRNAs) are conserved non-protein-coding RNAs that are naturally present in organisms and can control gene expression by suppressing the translation of mRNA or causing the degradation of mRNA. MicroRNAs are highly concentrated in the …

siRNA-based strategies to combat drug resistance in gastric cancer

Chemotherapy is a key treatment option for gastric cancer, but over 50% of patients develop either inherent or acquired resistance to these drugs, resulting in a 5-year survival rate of only about 20%. The primary treatment for advanced gastric …

Single-cell RNA sequencing to map tumor heterogeneity in gastric carcinogenesis paving roads to individualized therapy

Gastric cancer (GC) is a highly heterogeneous disease with a complex tumor microenvironment (TME) that encompasses multiple cell types including cancer cells, immune cells, stromal cells, and so on. Cancer-associated cells could remodel the TME …

Keynote webinar | Spotlight on cardio-oncology

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.

Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández
Watch now

CME & eLearning

Patient Cases

Take on interactive case studies with a focus on hematology. Each case has been prepared by renowned experts in the field and features knowledge-check questions with answers to help keep you and your practice up to date.

Developed by: Springer Medizin

Further Reading

Racial/ethnic differences in risk factors for non-cardia gastric cancer: an analysis of the Multiethnic Cohort (MEC) Study

In 2023, it is estimated that there will be 26,500 new gastric cancer (GC) cases and 11,130 GC-related deaths in the United States (US) [ 1 ]. Unfortunately, only 28% of cases are expected to be diagnosed in localized stages when patients are …

The Impact of ERAS and Multidisciplinary Teams on Perioperative Management in Colorectal Cancer

Colorectal cancer (CRC) represents a significant and growing global health challenge, affecting both worldwide populations and China, where incidence and mortality rates are on the rise [ 1 ]. Surgical intervention remains the cornerstone of CRC …